Hepatitis C testing rate low and knowledge of the infection poor in the US "baby boomer" generation
Standard hepatitis C therapy improves insulin resistance in HIV/hepatitis C co-infected patients
BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis
Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir
Promising findings for therapeutic hepatitis C vaccine TG4040
Depression and pegylated interferon: doctors look at screening strategies and treatment
Co-infection with hepatitis C increases mortality risk by 50% for patients with AIDS
Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity
GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks